1. Home
  2. NTRA vs CHTR Comparison

NTRA vs CHTR Comparison

Compare NTRA & CHTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$212.07

Market Cap

29.1B

Sector

Health Care

ML Signal

HOLD

Logo Charter Communications Inc. New

CHTR

Charter Communications Inc. New

HOLD

Current Price

$145.82

Market Cap

24.4B

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTRA
CHTR
Founded
2003
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Cable & Other Pay Television Services
Sector
Health Care
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
29.1B
24.4B
IPO Year
2015
1999

Fundamental Metrics

Financial Performance
Metric
NTRA
CHTR
Price
$212.07
$145.82
Analyst Decision
Strong Buy
Hold
Analyst Count
15
14
Target Price
$259.07
$271.50
AVG Volume (30 Days)
1.3M
2.9M
Earning Date
05-07-2026
04-24-2026
Dividend Yield
N/A
N/A
EPS Growth
0.65
3.55
EPS
N/A
9.17
Revenue
$210,939,000.00
$54,774,000,000.00
Revenue This Year
$18.08
$1.62
Revenue Next Year
$19.65
$0.09
P/E Ratio
N/A
$15.18
Revenue Growth
N/A
N/A
52 Week Low
$131.81
$126.70
52 Week High
$256.36
$420.33

Technical Indicators

Market Signals
Indicator
NTRA
CHTR
Relative Strength Index (RSI) 51.37 45.38
Support Level $186.96 $136.63
Resistance Level $222.53 $150.54
Average True Range (ATR) 10.51 5.85
MACD 0.34 2.60
Stochastic Oscillator 51.46 74.57

Price Performance

Historical Comparison
NTRA
CHTR

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

About CHTR Charter Communications Inc. New

Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 59 million US homes and businesses, around 35% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest US cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (Los Angeles Lakers), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1. Charter plans to acquire cable peer Cox.

Share on Social Networks: